Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off

Core Insights - Pfizer is currently facing challenges in generating growth, with its stock declining since 2021 when it last saw a significant gain of over 60% due to strong demand for COVID products [1][2] - Despite current struggles, Pfizer's management is optimistic about future growth, citing multiple potential catalysts and plans to launch over 20 pivotal late-stage trials in 2026 [3][4] Company Performance - Pfizer's stock has been trading at a deep discount, currently priced at $25.77, down 3.32% on the day, with a market cap of $152 billion [5][6] - The stock is trading at an estimated 9 times its forward earnings, significantly lower than the average S&P 500 stock, which trades at 22 times its estimated future profits [6] Investment Appeal - Pfizer offers a high dividend yield of 6.45%, making it an attractive option for investors seeking safe dividend stocks [6][7] - The potential for positive news from ongoing trials could lead to a rally in Pfizer's stock, which has been undervalued for an extended period [4][8]